## Human FcRn / FCGRT & B2M Heterodimer Protein

<table>
<thead>
<tr>
<th>Description</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Source</strong></td>
<td>Human FcRn / FCGRT &amp; B2M heterodimer protein, Ala 24 - Ser 297 (FCGRT, NP_001129491.1) and &amp; Ile 21 - Met 119 (B2M, AAH32589), was produced in human 293 cells (HEK293)</td>
</tr>
<tr>
<td><strong>Predicted N-terminus</strong></td>
<td>Ala 24(FcRN) &amp; Ile 21(B2M)</td>
</tr>
<tr>
<td><strong>Protein Structure</strong></td>
<td><img src="image" alt="Protein Structure Diagram" /></td>
</tr>
<tr>
<td><strong>Molecular Characterization</strong></td>
<td>Human FcRn / FCGRT &amp; B2M heterodimer protein, produced by co-expression of FcRn and B2M, has a calculated MW of 31.2 kDa (FCGRT / FcRN) and 13.1 kDa (B2M). Subunit FCGRT / FcRN is fused with his-tag at the C-terminus and subunit Beta-2 microglobulin (B2M) is fused with Strep II-tag at the C-terminus. The predicted N-terminus is Ala 24(FcRN) &amp; Ile 21(B2M). The reducing (R) protein migrates as 33 kDa (FCGRT) and 13 kDa (B2M) respectively due to glycosylation.</td>
</tr>
</tbody>
</table>

**Endotoxin**
Less than 1.0 EU per μg by the LAL method.

**Purity**
>95% as determined by SDS-PAGE.

**Bioactivity**
1. Measured by its binding ability in a functional ELISA. Immobilized Yervoy Ipilimumab (Human IgG1) at 10 μg/mL (100 μL/well) can bind Human FcRn / FCGRT & B2M (Cat# FCM-H5286) with a linear range of 0.06-5 μg/mL.
2. Measured by its binding ability to human IgG1 in a SPR assay (Biacore 2000). Immobilized Human FcRn / FCGRT & B2M can bind human IgG1 with affinity constant of μM range.

**Formulation and Storage**

| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally Trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation. |
| Reconstitution | Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the COA. |
| Storage | For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution. |

**Background**
FCGRT & B2M heterodimer protein (FcRn complex) consist of two subunits: p51 (equivalent to FCGRT), and p14 (equivalent to beta-2-microglobulin), and forms an MHC class I-like heterodimer. Fc fragment of IgG, receptor, transporter, alpha (FCGRT) binds to the Fc region of monomeric immunoglobulinss gamma and mediates the uptake of IgG from milk. FCGRT possible role in transfer of immunoglobulin G from mother to fetus. Beta-2-microglobulin (B2M) is a component of the class I major histocompatibility complex (MHC) and involved in the presentation of peptide antigens to the immune system.

**References**
**Assay Data**

**SDS-PAGE Data**

Human FcRn / FCGRT & B2M on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

**Bioactivity Data**

Immobilized Yervoy Ipilimumab (Human IgG1) at 10 μg/mL (100 μL/well) can bind Human FcRn / FCGRT & B2M (Cat# AMS.FCM-H5286) with a linear range of 0.06-5 μg/mL.